Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1621 1629
This examiner grants 62% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18925790 | NEW USE OF RECA INHIBITOR AND DERIVATIVE COMPOUNDS FOR CANCER TREATMENT | Non-Final OA | United Arab Emirates University |
| 18809439 | SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | Non-Final OA | AbbVie Inc. |
| 18312998 | IRON-COBALT-BASED MAGNETICALLY RECOVERABLE CATALYSTS AND METHOD OF PREPARATION THEREOF | Non-Final OA | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS |
| 19285330 | PHARMACEUTICAL COMPOSITION COMPRISING MELOXICAM | Non-Final OA | Mylan Laboratories LTD |
| 17349207 | AGENT FOR IMPROVING MUSCLE QUALITY | Non-Final OA | AJINOMOTO CO., INC. |
| 18694175 | N-SUBSTITUTED FERROPORTIN INHIBITORS | Non-Final OA | VIFOR (INTERNATIONAL) AG |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy